Abstract：
Receptor tyrosine kinases (RTKs) are cell surface receptors with kinase activity that play a crucial role in diverse cellular processes. Among the RTK family members, Human epidermal growth factor receptor 2 (HER2) and HER3 are particularly relevant to breast cancer. The review delves into the complexities of receptor tyrosine kinase interactions, resistance mechanisms, and the potential of anti-HER3 drugs, offering valuable insights into the clinical implications and future directions in this field of study. It assesses the potential of anti-HER3 drugs, such as pertuzumab, in overcoming resistance observed in HER2-positive breast cancer therapies. The review also explores the resistance mechanisms associated with various drugs, including trastuzumab, lapatinib, and PI3K inhibitors, providing insights into the intricate molecular processes underlying resistance development. The review concludes by emphasizing the necessity for further clinical trials to assess the efficacy of HER3 inhibitors and the potential of developing safe and effective anti-HER3 treatments to improve treatment outcomes for patients with HER2-positive breast cancer.
摘要：
受体酪氨酸激酶（RTK）是具有激酶活性的细胞表面受体，在多种细胞过程中起着至关重要的作用。在RTK家族成员中，人表皮生长因子受体2(HER2)和HER3与乳腺癌特别相关。这篇综述深入研究了受体酪氨酸激酶相互作用的复杂性，抵抗机制，以及抗HER3药物的潜力，为这一研究领域的临床意义和未来方向提供有价值的见解。它评估了抗HER3药物的潜力，如帕妥珠单抗，克服在HER2阳性乳腺癌治疗中观察到的耐药性。该综述还探讨了与各种药物相关的耐药机制，包括曲妥珠单抗,拉帕替尼,和PI3K抑制剂，提供有关抗性发展的复杂分子过程的见解。该综述最后强调了进一步临床试验的必要性，以评估HER3抑制剂的疗效，以及开发安全有效的抗HER3治疗以改善HER2阳性乳腺癌患者治疗结果的潜力。
